Pharmacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon‐Like Peptide‐2 (GLP‐2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects
- 1 November 2008
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (11) , 1289-1299
Abstract
Teduglutide, a glucagon‐like peptide‐2 (GLP‐2) analog, is currently being evaluated for the treatment of short‐bowel syndrome, Crohn's disease, and other gastrointestinal disorders. The pharmacokinetics, safety, and tolerability of teduglutide in healthy subjects (N =64) were assessed following daily subcutaneous administrations for 8 days in a double‐blinded, randomized, placebo‐controlled, ascending‐dose study. Teduglutide treatments were administered as a 50‐mg/mL (10, 15, 20, 25, 30, 50, and 80 mg) or 20‐mg/mL (20 mg) formulation. Blood samples were collected on days 1 and 8, and plasma concentrations of teduglutide were measured using a liquid chromatography/tandem mass spectrometry method. Mean systemic exposures to teduglutide were very similar on days 1 and 8, suggesting minimal, if any, accumulation following once‐daily repeated administrations. The apparent clearance of teduglutide following administration of the 50‐mg/mL formulation was constant over the dose range, with mean values in male and female subjects of 0.155 and 0.159 L/h/kg, respectively. Peak plasma concentrations and total exposure of teduglutide after subcutaneous injection of a 20‐mg/mL formulation (1.0 mL) were approximately 15% and 78% higher than those observed with the 50‐mg/mL formulation (0.4 mL), respectively. Teduglutide treatments were safe and well tolerated. All but 1 adverse event was assessed as mild or moderate in severity. No relationship between teduglutide treatments and frequency of adverse events was observed, with the exception of injection site pain, which increased as a function of dose and injected volume. Results from the current study will assist in the dose selection in future efficacy studies.Keywords
This publication has 16 references indexed in Scilit:
- Review article: glucagon‐like peptide 2 – current applications and future directionsAlimentary Pharmacology & Therapeutics, 2007
- Teduglutide for the Treatment of Short Bowel SyndromeAnnals of Pharmacotherapy, 2006
- Gut hormones, and short bowel syndrome: The enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptationWorld Journal of Gastroenterology, 2006
- Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patientsGut, 2005
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Medical treatment of active Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2002
- In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in HumansThe Journal of Clinical Endocrinology & Metabolism, 2000
- Structural Determinants for Activity of Glucagon-like Peptide-2Biochemistry, 2000
- Transaminase elevation on placebo during Phase I trials: prevalence and significanceBritish Journal of Clinical Pharmacology, 1999
- Ulcerative colitis and Crohn's diseaseBMJ, 1994